(R)-benzylsuccinic acid t-butyl ester | 1093232-38-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-benzylsuccinic acid t-butyl ester
• 英文别名: (3R)-3-benzyl-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid
• CAS: 1093232-38-2
• 化学式: C₁₅H₂₀O₄
• 分子量: 264.321
• InChiKey: ZVZVJDYXMTUDLY-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 (R)-benzylsuccinic acid t-butyl ester 在 N-甲基吗啉 、 叔-丁基氯甲酸酯 、 氢溴酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Optical 2-benzyl-5-hydroxy-4-oxopentanoic acids against carboxypeptidase A: Synthesis, kinetic evaluation and X-ray crystallographic study

  摘要：

  2-Benzyl-5-hydroxy-4-oxopentanoic acid 1 and its enantiomers were designed, synthesized and assayed for inhibitory activity against carboxypeptidase A (CPA, EC 3.4.17.1). To verify the role of the terminal hydroxyl group in 1 binding to CPA, 2-benzyl-5-benzyloxy-4-oxopentanoic acid 2 was also synthesized and evaluated. The inhibition constants show that both L-1 and D-1 were shown to have strong binding affinity with L-1 being more potent than its enantiomer by 165-fold. On the other hand, the inhibition constant of 2 increases 4-fold comparing with that of 1. In order to explore the exact binding mode of the hydroxyacteyl group of 1 to the active site zinc ion of CPA, we have solved the crystal structure of CPA complexed with L-1 up to 1.85 A resolution. In CPA-L-1 complex, the phenyl ring is fitted in the substrate recognition pocket at the S, subsite, and the carboxylate forms bifurcated hydrogen bonds with the guanidinium moiety of Arg-145 and Arg-127 and a hydrogen bond with the phenolic hydroxyl of the down-positioned Tyr-248. The carbonyl oxygen of L-1 does coordinate to the active site zinc ion of CPA as expectedly. Unexpectedly, the terminal hydroxyl group of L-1 is engaged in hydrogen bonding with carbonyl oxygen of Ser-197 instead of coordinating to the active site zinc ion. (C) 2009 Guan Rong Tian. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All fights reserved.

  DOI：

  10.1016/j.cclet.2009.09.005

文献信息

• COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS
  申请人：Hoveyda Hamid

  公开号：US20110230477A1

  公开（公告）日：2011-09-22

  The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.

  本发明涉及式（I）的新化合物及其在治疗代谢性疾病方面的应用。
• Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
  申请人：Euroscreen S.A.

  公开号：EP2364297A1

  公开（公告）日：2011-09-14
• [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET MÉTHODES POUR APPLICATION AU TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：EUROSCREEN SA

  公开号：WO2010066682A1

  公开（公告）日：2010-06-17

  The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.
• [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS POUR UTILISATION DANS LE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX
  申请人：EUROSCREEN SA

  公开号：WO2011076732A1

  公开（公告）日：2011-06-30

  The present invention relates to compounds of formula (I) useful in treating and/or preventing gastrointestinal disorders.
• [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS POUR UTILISATION DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：EUROSCREEN SA

  公开号：WO2011076734A1

  公开（公告）日：2011-06-30

  The present invention relates to compounds of formula (I) (I) useful in treating and/or preventing inflammatory diseases.